Evidence map›Paper›PMID 34162177›Full record

ArticleHaematologica2022

Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.

Sara Napoli, Luciano Cascione, Andrea Rinaldi, Filippo Spriano, Francesca Guidetti, Fangwen Zhang, Maria Teresa Cacciapuoti, Afua Adjeiwaa Mensah, Giulio Sartori, Nicolas Munz and 8 more

Open access · greenAbstract read
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 4 countries.

Sara NapoliInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona. sara.napoli@ior.usi.ch.
Luciano CascioneInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; SIB Swiss Institute of Bioinformatics, Lausanne.
Andrea RinaldiInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Filippo SprianoInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Francesca GuidettiInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Fangwen ZhangInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Maria Teresa CacciapuotiPathology and Laboratory Medicine Department, Weill Cornell Medicine, New York, NY.
Afua Adjeiwaa MensahInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Giulio SartoriInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Nicolas MunzInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona.
Mattia ForcatoCenter for Genome Research, Department of Life Sciences University of Modena and Reggio.
Silvio BicciatoCenter for Genome Research, Department of Life Sciences University of Modena and Reggio.
Annalisa ChiappellaEmatologia, A.O.U. Città della Salute e della Scienza di Torino, Turin.
Paola GhioneDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, 10021.
Olivier ElementoInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.
Leandro CerchiettiDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, 10021.
Giorgio InghiramiPathology and Laboratory Medicine Department, Weill Cornell Medicine, New York, NY.
Francesco BertoniInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland; Oncology Institute of Southern Switzerland, Bellinzona. francesco.bertoni@ior.usi.ch.
Institute of Oncology Research · CHCornell University · USUniversity of Modena and Reggio Emilia · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITLander Institute · ILSIB Swiss Institute of Bioinformatics · CH

Funding

Preclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI SCOTT, DAVID WILLIAM · 2018 to 2022
$10.2M
NCI NIH HHS P01 CA229100
6 · The paper itself

Abstract

Enhancers are regulatory regions of DNA, which play a key role in cell-type specific differentiation and development. Most active enhancers are transcribed into enhancer RNA (eRNA) that can regulate transcription of target genes by means of in cis as well as in trans action. eRNA stabilize contacts between distal genomic regions and mediate the interaction of DNA with master transcription factors. Here, we characterized an enhancer eRNA, GECPAR (germinal center proliferative adapter RNA), which is specifically transcribed in normal and neoplastic germinal center B cells from the super-enhancer of POU2AF1, a key regulatory gene of the germinal center reaction. Using diffuse large B-cell lymphoma cell line models, we demonstrated the tumor suppressor activity of GECPAR, which is mediated via its transcriptional regulation of proliferation and differentiation genes, particularly MYC and the Wnt pathway.

Indexed as

Enhancer Elements, GeneticLymphoma, Large B-Cell, DiffuseHumansRNARNA, UntranslatedTranscription, GeneticRNARNA, Untranslated

Identifiers

PMID34162177
PMCPMC9052922
OpenAlexW3175625418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.